Wockhardt Limited, a pharmaceutical and biotechnology company, manufactures and markets active pharmaceutical ingredients, formulations, bio-similars, and vaccines in India, the United States, Europe, and internationally. It provides pharmaceutical products in the therapeutic areas of anti-infective, cardiology, dermatology, diabetology, neurology, pain management, respiratory, and other areas. The company offers generic products that comprise injectables, including cephalosporins and non-cephalosporins; molecules; and value-added generics. Its biopharmaceutical products include Glaritus, an insulin analog; Wosulin, an r-DNA insulin; Wepox, a recombinant erythropoietin that is used in the treatment of anemia caused by cancer and chronic renal failure; and Biovac-B, a hepatitis B vaccine. The company also provides contract manufacturing services for sterile injectables, lyophilisation, and other dosage forms; and research services. It develops various molecules primarily in the area of anti-infectives, which include WCK 771 and WCK 2349 that is in Phase II human clinical trials for the treatment of staphylococcal infections; and WCK 5222, WCK 4282, WCK 4873, and WCK 6777 lead molecules, which are under pre-clinical trials. The company was incorporated in 1999 and is headquartered in Mumbai, India. Wockhardt Limited is a subsidiary of Themisto Trustee Company Private Limited. The ISIN of this stock is INE049B01025.